Vitae Pharmaceuticals, Inc 4
4 · Vitae Pharmaceuticals, Inc · Filed Oct 1, 2014
Insider Transaction Report
Form 4
VENROCK MANAGEMENT III LLC
10% Owner
Transactions
- Conversion
Common Stock
[F1][F2]2014-09-29+48,333→ 48,333 total(indirect: See Footnote) - Conversion
Common Stock
[F1][F3]2014-09-29+214,820→ 214,820 total(indirect: See Footnote) - Conversion
Common Stock
[F1][F4]2014-09-29+5,367→ 5,367 total(indirect: See Footnote) - Conversion
Common Stock
[F5][F2]2014-09-29+227,117→ 275,450 total(indirect: See Footnote) - Conversion
Common Stock
[F5][F3]2014-09-29+1,009,414→ 1,224,234 total(indirect: See Footnote) - Conversion
Common Stock
[F5][F4]2014-09-29+25,233→ 30,600 total(indirect: See Footnote) - Conversion
Common Stock
[F5][F2]2014-09-29+9,285→ 284,735 total(indirect: See Footnote) - Conversion
Common Stock
[F5][F3]2014-09-29+41,270→ 1,265,504 total(indirect: See Footnote) - Conversion
Common Stock
[F5][F4]2014-09-29+1,031→ 31,631 total(indirect: See Footnote) - Purchase
Common Stock
[F2]2014-09-29$8.00/sh+139,019$1,112,152→ 423,754 total(indirect: See Footnote) - Purchase
Common Stock
[F3]2014-09-29$8.00/sh+617,868$4,942,944→ 1,883,372 total(indirect: See Footnote) - Purchase
Common Stock
[F4]2014-09-29$8.00/sh+15,446$123,568→ 47,077 total(indirect: See Footnote) - Conversion
Series A-2 Preferred Stock
[F1][F2]2014-09-29−32,086→ 0 total(indirect: See Footnote)→ Common Stock (48,333 underlying) - Conversion
Series A-2 Preferred Stock
[F1][F3]2014-09-29−142,607→ 0 total(indirect: See Footnote)→ Common Stock (214,820 underlying) - Conversion
Series A-2 Preferred Stock
[F1][F4]2014-09-29−3,563→ 0 total(indirect: See Footnote)→ Common Stock (5,367 underlying) - Conversion
Series B Preferred Stock
[F5][F2]2014-09-29−227,117→ 0 total(indirect: See Footnote)→ Common Stock (227,117 underlying) - Conversion
Series B Preferred Stock
[F5][F3]2014-09-29−1,009,414→ 0 total(indirect: See Footnote)→ Common Stock (1,009,414 underlying) - Conversion
Series B Preferred Stock
[F5][F4]2014-09-29−25,233→ 0 total(indirect: See Footnote)→ Common Stock (25,233 underlying) - Conversion
Series C Preferred Stock
[F5][F2]2014-09-29−9,285→ 0 total(indirect: See Footnote)→ Common Stock (9,285 underlying) - Conversion
Series C Preferred Stock
[F5][F3]2014-09-29−41,270→ 0 total(indirect: See Footnote)→ Common Stock (41,270 underlying) - Conversion
Series C Preferred Stock
[F5][F4]2014-09-29−1,031→ 0 total(indirect: See Footnote)→ Common Stock (1,031 underlying)
Footnotes (5)
- [F1]Each outstanding share of Series A-2 Preferred Stock automatically converted on a 1:1.50638118 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.
- [F2]The reportable securities are owned by Venrock Associates.
- [F3]The reportable securities are owned by Venrock Associates III, L.P. ("VA III"). Venrock Management III, LLC ("VM III") is the general partner of VA III. VM III disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein.
- [F4]The reportable securities are owned by Venrock Entrepreneurs Fund III, L.P. ("VEF III"). VEF Management III, LLC ("VEFM III") is the general partner of VEF III. VEFM III disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein.
- [F5]Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted on a 1:1 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.